MATRITECH REPORTS NOTIFICATION OF MARKETING APPROVAL IN JAPAN FOR ITS NMP22 BLADDERCHEK TEST

Matritech, Inc. (Amex: MZT) a leading developer of protein-based diagnostic products for the early detection of cancer, today announced it has been notified by its distribution partner in Japan that its point-of-care cancer diagnostic NMP22(R) BladderChek(R) Test received marketing approval from the Japanese Ministry of Health, Labor and Welfare for testing of bladder cancer. Matritech's Japanese distributor, Medical & Biological Labs. Co., Ltd. (MBL) has begun sales and distribution of BladderChek Test, which is now referenced on its website (http://www.mbl.co.jp/index.html).

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050714005453&newsLang=en)